These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8031461)

  • 1. [Opportunistic infections in AIDS: the benefits of an "umbrella strategy." From an interview with Professor Willy Rozenbaum].
    Rozenbaum W
    Allerg Immunol (Paris); 1994 Apr; 26(4):153-5. PubMed ID: 8031461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ansatipine: only preventive treatment available for opportunistic MAI infections in AIDS. From an interview with Dr. Agnes Mignon].
    Mignon A
    Allerg Immunol (Paris); 1994 Apr; 26(4):148, 151-3. PubMed ID: 8031460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of MAI infections in AIDS with Ansatipine: experience at a hospital. From an interview with Dr. Jean-Luc Meynard].
    Meynard JL
    Allerg Immunol (Paris); 1994 Apr; 26(4):155-7. PubMed ID: 8031462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The stakes in preventing opportunistic MAI infections in AIDS. From an interview with Dr. Patrick Philibert].
    Philibert P
    Allerg Immunol (Paris); 1994 Apr; 26(4):145-8. PubMed ID: 7913323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment review. Rifabutin.
    Co M
    J Assoc Nurses AIDS Care; 1994; 5(1):45-50. PubMed ID: 8167311
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with rifabutin in the treatment of mycobacterial infections.
    De Cian W; Sassella D; Wynne BA
    Scand J Infect Dis Suppl; 1995; 98():22-6. PubMed ID: 8867175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of wasting and opportunistic infections in HIV-infected patients in West Africa: a realistic and necessary strategy before antiretroviral treatment].
    Ledru é ; Sanou PT; Dembele M; Dahourou H; Zoubga A; Durand G
    Sante; 1999; 9(5):293-300. PubMed ID: 10657773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of atypical Mycobacterium infections in AIDS-patients].
    Internist (Berl); 1996 Apr; 37(4 Suppl):1-8. PubMed ID: 9131082
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifabutin for MAC questioned.
    Posit Aware; 1995; ():6. PubMed ID: 11362571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.
    Benson CA; Williams PL; Cohn DL; Becker S; Hojczyk P; Nevin T; Korvick JA; Heifets L; Child CC; Lederman MM; Reichman RC; Powderly WG; Notario GF; Wynne BA; Hafner R
    J Infect Dis; 2000 Apr; 181(4):1289-97. PubMed ID: 10762562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of opportunistic infections in HIV-infected adults].
    Furrer H; Malinverni R
    Ther Umsch; 1998 May; 55(5):302-9. PubMed ID: 9643128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifabutin prophylaxis against Mycobacterium avium complex infection.
    von Reyn CF; Brown ST; Arbeit RD
    N Engl J Med; 1994 Feb; 330(6):437; author reply 438. PubMed ID: 8129826
    [No Abstract]   [Full Text] [Related]  

  • 14. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
    Jacobson MA; French M
    AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nontuberculous mycobacteriosis; the present status and in the future. Infection with human immunodeficiency virus (HIV) and nontuberculous mycobacteriosis].
    Mizutani S
    Kekkaku; 1998 Feb; 73(2):87-92. PubMed ID: 9545702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of late-stage AIDS grows more complex.
    AIDS Alert; 1995 Apr; 10(4):50-2. PubMed ID: 11362247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New ophthalmic manifestations of presumed rifabutin-related uveitis.
    Arevalo JF; Russack V; Freeman WR
    Ophthalmic Surg Lasers; 1997 Apr; 28(4):321-4. PubMed ID: 9101573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rifabutin. An antibiotic against mycobacteria].
    Andersen AB
    Ugeskr Laeger; 1997 Nov; 159(46):6844-8. PubMed ID: 9412003
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.
    Cohn DL; Fisher EJ; Peng GT; Hodges JS; Chesnut J; Child CC; Franchino B; Gibert CL; El-Sadr W; Hafner R; Korvick J; Ropka M; Heifets L; Clotfelter J; Munroe D; Horsburgh CR
    Clin Infect Dis; 1999 Jul; 29(1):125-33. PubMed ID: 10433575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.